transhepatic sampling of blood in the portal venous system (TPVS) was used to; (1) localize hormone secreting tumors and help in differentiating tumors from diffuse disease (nesideoblastosis and hyperplasia with adenomata) in 9 patients with fasting hypoglycemia and hyperinsulinism, and (2) study the concentration and distribution of the immunoreactive peptides: insulin (IRI), gastrin (IG), glucagon (IRG). pancreatic polypeptide (hPP). and somatostatin (SRIF-LI), in the venous drainage of the uninvolved portion of the pancreas and GI tract. Localized elevations of IRl (64-920 pU/ml) predicted tumor localization in 6 patients with single tumors that were not demonstrable angiographically.
H

ORMONE-SECRETING
tumors of the gastrointestinal tract occur predominantly in the pancreas, and rarely in and around the duodenum and stomach. When these tumors are small, localization by angiography'.'. ' may fail. Abdominal ultrasound4 and computed tomography (CT) have proved of limited value. Insulinomas, for example, are not localized by these methods in 344 of cases. ' Ingemansson, et al.' tirst demonstrated the feasibility of percutaneous transhepatic sampling of blood from the portal venous system (TPVS) with identification of high IRI concentrations in the venous effluent at the site of a tumor. This technique has been employed by several groups in the successful localization of insulinoma& " and there have been three cases reported from the United States.'. ' Aside from insulinomas, tumors secreting gastrin," glucagon, '* somatostatin," " human pancreatic polypeptide (hPP),'O vasoactive intestinal polypeptide (VIP),"," mixed endocrine tumors," and diffuse islet cell adenomatosisZ4 have all been described as producing clinical syndromes.
Gastrinomas,'5.26 glucagonomas" and islet cell hyperplasia*" have been localized by hormone concentrations in the portal venous effluent. There has been no report of the concentration of hormone levels in the venous effluent of somatostatin-secreting or mixed endocrine tumors. The various hormone-secreting cells are not evenly distributed throughout the pancreas.29~30.3' This nonhomogeneity of hormone content, if reflected in portal venous hormone concentrations, may complicate interpretation of data obtained in patients with gastrin. glucagon, somatostatin or pancreatic polypeptide secreting tumors. For this reason it is important to establish the "normal" pattern of hormone secretion into the gut and pancreatic venous drainage.
We report here localization of tumors in five patients with single insulinomas; recognition of multicentric or diffuse disease in one patient with nesideoblastosis and one with islet hyperplasia and adenoma; and the diagnosis of a mixed insulinoma/somatostatinoma and insulinoma/glucagonoma.
We have also established the profile of hormone concentrations of gastrin, "pancreatic" glucagon, hPP and somatostatin-like immunoreactivity (SRIF-LI) in the portal venous system, and the portal-systemic concentration gradients of these peptides in humans. 
= macroadenoma + islet hyperplasia.
None of the patients had a personal or family history of multiple endocrine neoplasia.
AW had symptoms from age 1-17 yr which were thought to be due to a convulsive disorder; biochemical hypoglycemia was recognized for the first time at age 17 yr. There was some change in symptomatology between ages 17-20 yr; it was entertained that he may have developed fasting hypoglycemia during this period of time. Because the confusing nature of the history and intermittent hyperinsulinism. the patient was referred for differential diagnosis and treatment.
'Symptomatic hypoglycemia.
Tl/G = Insulin @J/ml/Glucose mg/dl ml = <0.3).
fAI/G = Amended I/G = insulin mg/dl/Glucose mg/dl -30 ml 5 50) (32).
SNormal Proinsulin ~22%.
//Operative fmdings.
MATERIALS AND METHODS
Patients
The clinical details of the 9 patients are given in Table 1 . 
Blood Sampling and Storage
Each blood sample (7-8 ml) was immediately aliquoted into two 
HORMONE ASSAYS
Insulin lmmunoreactive insulin was measured by a double-antibody RIA which detects total insulin in plasma." The least detection limit was 0. IS pU/tube, the intraassay variation was 3.2%. The mean 2 SE concentration of insulin in peripheral venous plasma from fasting healthy nonobese subjects was 10.9 i I.4 pU/ml.
Ga.vtrin
lmmunoreactive gastrins were measured by RIA using ion exchange resin to separate the bound from free-labeled peptide." The antisera (G2 Cape Town, South Africa) recognizes all forms of gastrin. Synthetic heptadecapeptide 1%Leu gastrin was used for labeling with 'I51 and l5-Met-gastrin as standard. The least detection limit was 0.16 pgjtube, the intraassay variation was 4%. The mean + SE concentration of gastrin in peripheral venous plasma of fasting healthy subjects was 45 I 9 pg/ml. Plasma levels of "pancreatic" glucagon (IRG) were measured using a double antibody RIA.j6 The antiserum.
G9-I (Ann Arbor. Michigan) used in the assay detects the C-terminal region of the glucagon molecule and has negligible (2%-5%) cross-reactivity with intestinal glucagon-like material (GLl). It does, however, detect glucagon of varying molecular weights. The mean ? SE plasma concentration of glucagon in fasting young adults was 64 ? 8 pg/ml. The least detection limit was 3.4 pg/tube. the intraassay variation was 4. I %
Pancreatic Polypeptide
Human pancreatic polypeptide was measured by double antibody RlA3' using '"51-labeled bPP as tracer (Eli Lilly Co. lot no. 615 D63-18%9), antiserum to hPP (Eli Lilly lot no. 615-1054B-248-19) and hPP (Eli Lilly & Co. lot no. 6 15-l 054B-200) as standard. The least detection limit was 2.5 pg/tube, the intraassay variation was 12%~. The levels of peripheral venous plasma hPP (mean + SD) in fasting healthy subjects by decades. 3-7 (263 subjects) were: 54 + 28, II5 + 98, 165 k 159, I81 2 166,207 -r 129 pg/ml.
Somatostatin
lmmunoreactive somatostatin (SRIF-11) was measured by RIA using charcoal to separate the bound and free-labeled hormone." The antiserum (I 374 Cape Town, South Africa) recognizes the C-terminal 6-l I aminoacid region. Tyr'-SRIF (courtesy of J. Rivier, Salk Institute, LaJolla, California) was labeled with "'1 to a specific activity of 1000 rCi/wg and repurified by cation exchange chromatography using Whatman CM,, cellulose and an ammonium acetate gradient of 0.05-500 mM. Plasma samples were not extracted. The assay was carried out at pH 5.3 in 50 mM ammonium acetate buffer containing 0.05% EDTA. Under these conditions, incubation of tracer in plasma for 48 hours resulted in less than 2% damage. adsorption to charcoal was 92% and nonspecific adsorption to plasma proteins was 2%. SRIF-LI added to plasma was completely recovered and serial dilutions of plasma were parallel to the synthetic standard.
The least detection limit was 1.75 pg/tube, the intraassay variation was 12%. SRIF-LI concentrations in unextracted peripheral venous plasma of fasted healthy subjects ranged between 50-300 pg/ml. Plasma glucose was measured by the procedure of Worthington Biochemical Company based on the coupled-enzyme method of Slein." using hexokinase and glucose-h-phosphate dehydrogenase. with modifications by Bondar and Mead.JO
RESULTS
In 6 of the 9 patients studied, pancreatic angiography, abdominal CT scan and ultrasound failed to identify a tumor where a single tumor was later found at operation; one in the head, three in the neck, one in the body, and one in the tail of the pancreas. All six of these tumors were localized by the maximum hormone level in the portal venous system (Table  2A -E). Figure 2A -E is a schematic representation of the sites of each tumor and the concentrations of insulin in the portal venous system in 5 of these patients. A sixth patient, ASa., had a single tumor in the neck of the pancreas (Fig. 3) . Elevated glucagon concentrations in the portal venous system (Fig. 3B ) adjacent to the elevated insulin concentrations suggested glucagon as well as insulin production by the tumor. The maximum IRI concentrations ranged from 64-941 gU/ml with a mean k SE of 452 f 140 &/ml (Table 2 ). The mean + SE of insulin concentrations in samples drawn simultaneously from the celiac artery was 43 f 9 pU/ml and that in the veins draining the uninvolved pancreas was 36.6 + 6.3 &/ml.
The gradient (tumor site-simultaneous arterial) ranged from 39-898 PU / ml with a mean k SE of 409 4 137 pU/ml.
In a seventh patient (A.W., Table IG islet insulin-containing ductal cells and large, irregularly-shaped islet cells as well as normal-appearing islets were particularly frequent in the head of the pancreas corroborating the findings at TPVS that the most marked elevation of IRI was in the venous drainage of the head of the pancreas.
In the 2 remaining patients angiography did demonstrate the presence of a tumor. Patient A.S. (Fig. 4B ) who had an angiographically demonstrated tumor in the tail of the pancreas had on TPVS elevated IRI concentrations in the midsplenic vein, inferior mesenteric vein (IMV), posterior superior pancreaticoduodenal (PSPDV). and the dorsal pancreatic vein. suggestive of a multicentric or diffuse process. This patient had undergone pancreatic surgery I yr earlier for hyperinsulinism with the enucleation of a single adenoma from the tail of the pancreas. At surgery this time, only the angiographically demonstrable tumor was palpable and frozen section examination of adjacent pancreas was "normal."
Because of the demonstration by TPVS of non-localized disease, enucleation of the tumor was not attempted and a distal 2/3 pancreatectomy was done. Histologic examination
GLASER ET AL.
confirmed the presence of a single, lobulated adenoma and demonstrated associated diffuse islet cell hyperplasia.
Patient S.P., who presented with fasting hypoglycemia and hyperinsulinemia, had a large tumor (32 g) of the head of the pancreas which was easily demonstrated angiographically.
The highest insulin concentrations were found in the proximal superior mesenteric vein at or near the confluence with the splenic vein (Fig. 5A) . High values of SRI F-LI were found in a distribution similar to that of insulin (Fig. 5B ) suggesting that the tumor produced SRIF-LI as well.
None of the 9 patients has had recurrence of symptoms of organic hyperinsulinism.
One patient (A.W.) is an insulin-requiring diabetic as a result of extensive resection of the pancreas.
In the six cases with small single adenomata, elevated concentrations of IRI were not always found exclusively in close proximity to the tumor. The highest concentration of insulin was found in the distal splenic vein in patient (A.B.) with a tumor in the tail of the pancreas ( were also found in the proximal splenic vein and in the gastrocolic trunk. A venous communication between the tail of the pancreas and the superior mesenteric vein via the gastroepiploic veins was visualized at surgery (Fig. 6) . Patient N.H. had a tumor in the body of the pancreas. The highest concentration of insulin was found just distal to the tumor location in the splenic vein. However, there was also a lesser elevation proximal to this site. Direct drainage of a tumor located in the neck of the pancreas into the portal vein could be demonstrated at surgery in patient R.S. (Fig.  7) . Duplicate sampling from the same site (Table 3) in the portal venous system at different times occasionally gave differing IRI concentrations. In the 5 patients with single insulinomas, the mean concentrations of IG, IRG, hPP and SRIF-LI in the portal venous system are given in Table 4 along with the portal/systemic gradients. Patients A.W. and A.S. were excluded from this analysis because of their diffuse disease process which may be associated with other islet hormone abnormalities.
R.S. 21, Female
Patient S.P. and ASa. were excluded because their tumors produced more than one hormone, a situation that may affect the secretory patterns of other hormones. The highest concentration and significant gradient of gastrin was found in the gastrocolic trunk; hPP gradient was greatest in the proximal-portal vein; SRIF-LI gradient was greatest in the superior-mesenteric vein and gastroepiploic vein; IRG concentrations were similar at all locations with positive gradients throughout the portal venous system.
DISCUSSION
We have carried out transhepatic portal venous sampling to; ( I ) localize insulin-producing tumors and to help in differentiating single tumors from diffuse disease (nesideoblastosis and hyperplasia with adenoma) and (2) determine concentrations of other gut/ pancreatic hormones in the portal venous system.
We have studied 6 patients with small single adenomas that were not angiographically demonstrable and have confirmed the findings of others6-" that even small tumors (<I cm) can be localized preoperatively using the technique of TPVS. In 5 of these 6 patients, preoperative localization by TPVS was helpful to the surgeon in directing him to the tumor site since it was not easily palpable at initial exploration.
Two patients with diffuse pancreatic disease were also studied. One, AS., had a single lobulated tumor demonstrated angiographically preoperatively, however, the history of prior removal of another ademona suggested the presence of multiple adenomatosis. At surgery, a single tumor was found, associated with diffuse hyperplasia.
The other patient, A.W., had in retrospect a history suggestive of hypoglycemia dating from one year of age, however, biochemical hypoglycemia was not recognized until age 17 yr (Table I) . Nesideoblastosis was found at operation. Both of these patients had multiple areas of elevated IRI concentrations suggesting that: (I) both these processes are non-homogeneous, and (2) TPVS cannot differentiate nesideoblastosis from hyperplasia with adenoma. Multifocal, nonhomogeneous secretion of insulin was found in a patient with hyperplasia without adenomata by Ingemansson.2x
Thus, nesideoblastosis and hyperplasia with and without adenomata cannot be distinguished by the hormonal profile in TPVS. The interpretation of data obtained during these and similar studies requires an appreciation of the complexity and variability of the venous drainage of the pancreas and proximal gut. We have demonstrated that a tumor in the tail of the pancreas can drain into the gastroepiploic vein (A.B.) resulting in high hormone levels remote from the actual tumor site (Fig.  6) . The high insulin concentration noted near the confluence of the splenic and superior mesenteric veins in the same patient (Fig. 2E ) may be related to tumor drainage through the short gastric veins into the coronary vein which enters at that point. The findings of a moderately elevated concentration of insulin in the splenic vein proximal to the tumor in patient N.H. may relate to variabilities of venous admixture, or catheter placement. Such findings may present difficulties in differentiation of patients with single tumors from those with diffuse disease who have elevated concentrations found at multiple remote sites such as patient A.S. whose elevated IRI concentrations in the PSPDV is not compatible with collateral drainage from a tumor in the body or tail of the pancreas.
A tumor of the head of the pancreas (E.V.) could be identified by high insulin levels in the area of drainage into the superior pancreaticoduodenal vein, while one in the neck of the pancreas (R.S.) drained into the proximal portal vein close to the junction of the superior mesenteric and splenic veins. A tumor of the body of the pancreas (N.H.) drained into the midsplenic vein. A maximum insulin concentration as low as 64 wU/ml or a tumor site-arterial gradient of 39 &l/ml may be sufficient to localize a tumor. Values as low as 41 9 and 62 pU/mlx have been reported.
Repeated sampling at the same location at different times can yield variable hormone concentrations. This variability may be due to a minor error in estimating catheter location, laminar Row of blood within major veins, or pulsatile hormone secretion. In none of our cases did this problem result in error of localization however. multiple site samplings and repetitive samplings at different times may help in identifying spuriously elevated or suppressed levels.
Two patients had evidence on TPVS of multiple hormone production by their tumors. The normal peripheral glucagon concentrations, even though there was excessive glucagon output by the tumor in patient A.Sa., explain the absence of the usual stigmata of the GLASER ET AL. glucagonoma syndrome such as migratory necrolytic erythema. The other patient (S.P.) had a large tumor, but relatively low fasting IRI concentrations. The finding of excessive SRIF secretion from the tumor may explain why IRI concentrations were not higher and hypoglycemic symptoms were not more severe. That there were none of the features of somatostatin excess-steatorrhea, achlorhydria or gall bladder disease,'3m'9 may be related to the relatively low (400 pg/ml) circulating SRIF concentrations.
In patients with symptomatic somatostatinomas, peripheral venous concentrations were generally > 1000 pg/ml.'3m'9 The use of TPVS for the evaluation of patients with organic hyperinsulinism is indicated only after a definitive diagnosis has been made using the appropriate clinical and laboratory tests, and only in those patients where a tumor has not been located angiographically or when a diffuse process is suspected. Patients with recurrent hypoglycemia after removal of an insulinoma, patients with multiple endocrine neoplasia Type I (MEN-l) or with a family history of MEN-I often have diffuse pancreatic disease and even if a single adenoma is demonstrated angiographically, TPVS is indicated before operation. The use of TPVS in patients with a clinical presentation of a single insulinoma demonstrable angiographically is not justified at this time as the procedure is not innocuous. although we encountered no major complications in the nine patients studied.
Most of these patients complained of severe right flank and epigastric pain during the procedure despite narcotic analgesia and sedation. This pain persisted for l-2 days, but rarely required further analgesia after the first 4-6 hr. Seven of the nine patients were ambulatory and could be discharged 24 hr after the procedure was completed, though two remained hospitalized for further testing. One patient (R.S.) had a decrease in hematocrit following the procedure, probably related to bleeding into the thigh at the site of arterial puncture, but blood loss from the transhepatic procedure cannot be entirely ruled out since stools, while grossly normal, were positive for occult blood. Another patient (A.W.) had flank tenderness, rebound tenderness, and an increase in abdominal girth, which resolved spontaneously after 72 hr. lmmunohistochemical studies have determined that gut/pancreatic hormones are not distributed evenly throughout the entire pancreas. By studying the concentrations of hormones other than insulin in the gut/pancreatic venous effluent of patients with single small insulinomas we have been able to obtain an estimation of the maximum concentrations and portal-systemic gradients of these hormones in the unaffected pancreas, and have also found this distribution to be non-homogeneous for gastrin, hPP and SRIF-LI, providing functional confirmation of the previous anatomical findings.
The maximum concentration of gastrin in the gastrocolic trunk is compatible with its origin from the gastric antrum and the absence of a significant gradient between the concentrations in the pancreatic venous effluent and the systemic circulation supports the observation that there are no gastrin cells in the adult human pancreas and that heptadecapeptide gastrin is not inactivated by passage through the liver.4"4'
The glucagon concentrations measured with this antiserum reflect "pancreatic" IRG. There is only 2%5% cross-reactivity with GLI. The levels in the peripheral venous system are lower than those reported in healthy subjects using Unger's 30 K antiserum and the portal vein/arterial gradient of 31% (Table 4) is acceptable for the known hepatic extraction of glucagon. 43 The positive gradients found in the superior mesenteric and gastrocolic trunk suggest secretion of a "pancreatic" type glucagon produced by the gut in humans and is in keeping with persistence of IRG in the circulation after total pancreatectomy in man. 44 The hPP concentrations in the portal vein were 30% greater than in the peripheral circulation.
A positive portal-peripheral venous concentration-difference indicating hepatic extraction of PP has been demonstrated,45,46.47 but not confirmed.4R The highly selective elevation of hPP levels only in the distal portal vein, could account for the failure48 to find a gradient, since 
HORMONE CONCENTRATIONS IN PORTAL SYSTEM
samples may have been taken at too proximal a site. The higher levels in the portal vein, close to the liver, adjacent to the posterior superior pancreaticoduodenal vein are in keeping with the anatomic localization of most of the PP cells in a separate lobe in the head of the pancreas.'q.3"
The fasting SRIF-Ll concentrations in the peripheral vein and celiac artery are similar to those reported in healthy subjects3' when unextracted plasma is used, but may be higher than levels found in extracted plasma. The greatest concentrations is the gastrocolic trunk and superior mesenteric veins suggest that in man most of the SRIF-LI secreted into the portal venous system derives from the proximal small gut corresponding with the greatest tissue levels found by extraction of the gut and pancreas in dog and man." These data will be necessary in the interpretation of future studies done for localization of tumors producing these hormones.
In our studies we have obtained celiac artery and/or peripheral venous samples simultaneously with portal samples. While these values were not needed in any of our cases to adequately localize the tumors, calculating portal-systemic gradients of SRIF-LI, glucagon, and hPP can be expected to add to the accuracy of localizing maximum concentrations and gradients by avoiding apparent differences due to rapid oscillations of hormone levels.
In summary.
we have localized by TPVS small angiographically-negative insulinomas in 6 patients. Some problems in interpretations of portal venous 1009 insulin concentrations are discussed. We have demonstrated the non-homogeneous pattern of IRI secretion in a patient with nesideoblastosis and one with islet hyperplasia and adenoma, making it impossible to distinguish these two entities by this procedure. We have demonstrated glucagon production by an insulinoma in a patient with normal peripheral plasma concentration of glucagon and SRIF production by a large insulinoma in a patient with normal peripheral plasma SRIF concentrations.
The procedure appears to be relatively safe albeit painful, and can be recommended for those patients with proven organic hyperinsulinism but negative pancreatic angiograms or those with recurrent hypoglycemia due to multiple tumors or MEN-I. We have also delineated some of the complexities of the pancreatic venous drainage and provided new information on the concentrations and gradients of IRG, hPP, SRIF-LI and gastrin in the portal venous system in man, which may be helpful in the interpretation of future studies. 
